First-line treatment of non-small cell lung cancer Pfizer's third generation APK inhibitors reached the stage 3 clinical endpoint.

Lung cancer is the leading cause of cancer-related deaths worldwide.
non-small cell lung cancer accounts for about 80-85% of lung cancer, and about 3-5% of non-small cell lung cancer cases carry APK-positive tumors.
patients with advanced NSCLC had a five-year survival rate of only 5% before they received targeted and immunotherapy.
Lorbrena is a tyrosine kinase inhibitor (TKI) that is highly active in preclinical lung cancer models that carry APK rear-rowing.
Lorbrena specializes in inhibiting APK gene mutations that are resistant to other APK inhibitors and penetrates the blood-brain barrier.
2018, the FDA accelerated approval of Lorbrena to treat patients treated with ALC-positive metastasis NSCLC.
the CROWN clinical trial for this accelerated approved validation trial.
based on the positive results of this trial, Pfizer will seek FDA approval to convert accelerated approval into full approval and seek approval for the treatment of patients with ALC-positive metastasis NSCLC. "We are pleased to share this data with physicians and other healthcare providers as soon as possible, as well as to work with regulators around the world to provide this third-generation APK inhibitor to patients with primary metastases of metastasis non-small cell lung cancer as soon as possible," said Dr. Chris Boshoff, Chief Development Officer, Global Product Development Oncology,
Pfizer.
"